The Dementia with Lewy Bodies Consortium (DLB Consortium or DLBC) is an international multidisciplinary collaboration of researchers interested in the dementia with Lewy bodies.
[1] Between 1995 and 2005, it issued three DLBC Consensus Reports on dementia with Lewy bodies.
[2] The 2017 rewrite of the diagnostic criteria for DLB[3] was led by Ian G. McKeith of Newcastle University and supported by The National Institute on Aging, National Institutes of Neurological Disorders and Stroke, the Lewy Body Dementia Association, the Lewy Body Society, Alzheimer’s Association, Acadia Pharmaceuticals, Axovant Sciences, Banner Health, GE Healthcare, and Lundbeck.
[4] The 2015 DLBC in the United States is a project of the Parkinson's Disease BioMarker Program of the National Institute of Neurological Disorders and Stroke that "establishes a group of centers dedicated to the study of dementia with Lewy bodies (DLB) ... to allow for the discovery of a biomarker for DLB to improve the diagnosis, care, and treatment of patients with this disease".
[5] The DLBC will "formalize and strengthen already existing collaboration among the participating centers".